Market Signal Briefing

The stock has lagged broader equities this year, but patient investors who initiate positions today might be very well rewarded in a decade.

Over the past 25 years, Intuitive Surgical (ISRG 0.13%) has experienced significant success thanks to its pioneering use of robotics in surgery. The healthcare leader now stands as the undisputed top player in the robotic-assisted surgery (RAS) market. However, things are changing, and Intuitive Surgical may face increased competition in the coming years that could disrupt its prospects.

Can the company maintain its leadership position while still delivering strong results and market-beating returns? Let's see how things might evolve for Intuitive Surgical over the next decade.

The first of several potential newcomers
Intuitive Surgical's da Vinci system is the company's best-known device. It has been approved across a range of procedures, and in many of them, it has little to no competition. But some healthcare giants are quickly looking to shake things up.

Image source: Getty Images.

First up, we have Medtronic, a medical device specialist. Medtronic completed clinical trials for its Hugo system in urologic procedures in the U.S. earlier this year. It is now awaiting regulatory clearance in that indication. And since announcing that win, Medtronic has also posted positive clinical trial results for the Hugo system in hernia repairs. The da Vinci system is approved for both urologic procedures and hernia repairs, so the two are heading straight for a collision.

Further, Medtronic is likely to seek additional indications that overlap with the da Vinci system. Meanwhile, another healthcare leader, Johnson & Johnson, is also developing an RAS system called Ottava. The device is currently in clinical trials for gastric bypass -- another one of the da Vinci system's indications -- in the U.S. It might be a few years before the Ottava hits the market, but it will add to Intuitive Surgical's competitive pressure.

Intuitive Surgical's advantages
Several factors could enable Intuitive Surgical to maintain its leadership position in the market. Let's consider two. First, its device not only has completed clinical trials and earned approvals across many indications, but it has also been in use in the real world for a long time. This first-mover advantage should give Intuitive Surgical an edge over newcomers in the field.

It has also allowed the company to get valuable feedback from healthcare professionals and modify its device as needed. The da Vinci system's fifth generation was launched just last year, with smashing success.

Today's Change

(

-0.13

%) $

-0.75

Current Price

$

573.48

Second, Intuitive Surgical already has a large installed base. It ended the third quarter with 10,763 installed da Vinci systems, representing a 13% year-over-year increase. Most of these are likely to remain in place. Not only is the device expensive, but it also requires a learning curve for surgeons to master. Switching to a competitor after putting in all that money, time, and effort is too much work for most healthcare facilities. Intuitive Surgical's switching costs are a powerful reason it should remain a leader.

It also allows for a recurring source of revenue. The instruments and accessories it sells for procedures have a short lifespan and need to be replaced regularly. And as procedure volume grows, so does the volume of accessories it sells.

Why Intuitive Surgical can still beat the market
Competition will intensify over the next decade, but robot-assisted procedures also should. One reason is that the market is severely underpenetrated. More players could help grow awareness, increase demand for the minimally invasive procedures they facilitate, and prompt even more hospital systems to invest in these devices.

Furthermore, the world's population is aging. By 2035, projections indicate that adults aged 65 and older will outnumber minors aged 18 and younger in the U.S. for the first time. This demographic shift will have significant implications for healthcare spending, as the elderly require more medical care, including the types of procedures that Intuitive Surgical offers with its da Vinci system. These tailwinds should help boost the company's procedure volume.

Intuitive Surgical has long generated steady revenue and earnings growth. It is still at it. And investors can expect much of the same over the next decade. The company could still deliver superior returns to patient investors.

SummaryNEOS Enhanced Income Credit Select ETF offers high-yield income by investing in high-yield bond ETFs and writing SPX put spreads.HYBI currently yields 8-9% with monthly distributions, but its portfolio leans toward riskier, below-investment-grade bonds.The fund's expense ratio is capped at 0.68%, and its performance is closely tied to the health of high-yield credit markets.Given the risk profile and lack of strong capital gain drivers, HYBI is rated as an adequate hold for income-focused investors. SSG PHOTO/iStock via Getty Images

NEOS Enhanced Income Credit Select ETF (HYBI) offers a balance between "junk" bonds and options writing for income. With a year on its belt, it's not done badly, but it also seems like it could disappoint under duress, for which

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

These funds offer yields that are more than three times the S&P 500 average.

Investing in the stock market today can be worrisome given how high valuations have become of late. That can add risk to your portfolio, and potentially make you vulnerable in the event of a correction -- or worse, a full-blown crash.

If you're in retirement and just want some steady, dependable income, the good news is that there are many reliable exchange-traded funds (ETFs) that can keep your risk low while providing solid returns. While the S&P 500 averages a yield of only 1.2%, there are ETFs that can give you much more in dividend income.

A couple of solid, dividend-focused ETFs you may want to consider today are the Vanguard International High Dividend Yield ETF (VYMI +0.26%) and the Schwab U.S. Dividend Equity ETF (SCHD +0.51%). Here's why these funds can be excellent options for your portfolio if your priority is dividend income.

Image source: Getty Images.

Vanguard International High Dividend Yield ETF
The Vanguard International High Dividend Yield ETF pays a fairly high yield of around 4%, which is easily more than three times the S&P 500 average. Meanwhile, it charges a low expense ratio of 0.17%.

This can be an attractive income investment if you're worried about the U.S. economy because it focuses on other markets. European stocks account for 43% of the ETF's holdings, followed by the Pacific region at 26%, and emerging markets make up another 22%. Overall, there are more than 1,500 stocks in this fund.

Another great feature about this ETF is how modest its holdings are -- no stock accounts for more than 2% of the overall portfolio. HSBC Holdings, Nestlé, and Novartis are currently its top three stocks, but together, they make up just 4.5% of the ETF's total holdings. That's great from a risk standpoint since it ensures that you aren't dependent on how just a few stocks perform, which is a big risk with many tech-heavy ETFs these days.

Today's Change

(

0.26

%) $

0.23

Current Price

$

87.72

The Vanguard fund has also averaged a beta of 0.92 over the past five years, which indicates that it is less volatile than the overall stock market. That doesn't mean that it won't struggle in a downturn, but it can be less volatile overall, which can be key if you just want to focus on dividend income.

Schwab U.S. Dividend Equity ETF
This is another top dividend ETF. As its name suggests, it focuses on U.S. dividend stocks. Together with the Vanguard fund, you can have a portfolio that encompasses both U.S. and international markets with just two investments.

The Schwab fund is much smaller in scope, with around 100 stocks in its portfolio. That can be a good thing with dividend stocks because it suggests a more carefully selected portfolio. The ETF's focus is on keeping costs low while targeting stocks that have strong financials and can sustain their dividend payments; it's not simply a huge collection of dividend-paying investments.

In this ETF, you'll find some top names when it comes to dividends, including Coca-Cola, AbbVie, and Cisco Systems. Those are among its top holdings. While there is a bit more exposure to individual stocks with this ETF, given its focus on quality dividend stocks, that doesn't take away from the overall safety with this fund.

Today's Change

(

0.51

%) $

0.14

Current Price

$

27.59

The Schwab ETF yields 3.8%, and its expense ratio of 0.06% is incredibly light. Meanwhile, its beta of 0.79 suggests it's an even less volatile investment than the Vanguard fund.

Although the ETF is down 1% this year, it has generated returns of around 30% in five years, and that's without including its dividend. Overall, it's a solid option for the long haul that can generate recurring income for the foreseeable future.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CLSK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Since 2023, these stocks have soared between 490% and 2,400%.

Generating a 50% return in one year is impressive. Doing it twice is amazing, and it might have you thinking that the stock is due for a letdown. But the stocks listed here are all on track to generate 50% returns for a third consecutive year in 2025.

Robinhood Markets (HOOD +0.23%), Palantir Technologies (PLTR +1.62%), and Sofi Technologies (SOFI +4.32%) have been among the hottest growth stocks to own since 2023. Here's a look at what's been behind their stellar gains in recent years, and if they still have more room to rise higher.

Image source: Getty Images.

Robinhood Markets
In 2023, Robinhood's stock rose by 57%, and then 193% the following year. Thus far in 2025, it's up even more -- 209% (returns as of Nov. 21). The company's trading platform is a hub for investing, trading, and betting. Whether it's buying stocks, crypto, or now making predictions, it's become a one-stop platform for a wide range of users.

The company has proven to be more than just a meme stock that's popular with retail investors. It has been generating some incredible growth, with phenomenal top- and bottom-line results. Robinhood recently posted its third-quarter earnings, and its revenue doubled to $1.3 billion for the period ending Sept. 30. Its Rule of 40 score over the trailing 12 months has been 131%, which is a key metric many growth investors focus on that factors in sales growth and earnings. It has been experiencing significant growth since expanding its prediction markets business, and that has the potential to be a growth catalyst for the foreseeable future as the company is even open to acquisitions to help expand that area of its operations quickly.

Today's Change

(

0.23

%) $

0.29

Current Price

$

128.49

Today, the stock's market cap is right around $100 billion, and it trades at a price-to-earnings (P/E) multiple of 48. It's an expensive stock to own, but with some exciting growth potential, I think a premium is justifiable for the business.

Palantir Technologies
Data analytics company Palantir Technologies has been another scorching-hot buy in recent years. Thus far in 2025, it's up around 115%, after skyrocketing 341% last year and 167% the year before that.

Retail hype is a big driving force with Palantir as its valuation is astounding, with a P/E multiple of around 380. A stock doesn't generate the type of returns Palantir does and trade at such a high valuation without strong support from retail investors. But that's not to say the company's results haven't been terrific; Palantir's sales rose by 63% in its most recent quarter (which ended on Sept. 30), totaling $1.2 billion. The company touts a Rule of 40 score of 114% as both its top and bottom lines have looked strong.

Today's Change

(

1.62

%) $

2.68

Current Price

$

168.45

But with a high share count, the company's valuation is rich on a per-share basis. A lot of artificial intelligence (AI) growth has been driving the stock's gains and the risk is if that slows down, that could be its undoing. In recent weeks the stock has been giving back some gains as investors grow concerned about valuations.

Given the risks, I wouldn't buy into Palantir's rally, as tempting as it might be, as there does appear to be considerable room for the stock to fall significantly in the event of a sell-off in the markets.

SoFi Technologies
Rounding out this list of high performers is SoFi Technologies. It's been rallying 78% this year after rising 55% last year and 116% back in 2023. One thing that it has in common with the other stocks listed here besides its impressive gains is that it's a popular company with retail investors.

SoFi has evolved over the years from student loan origination to offering a wide variety of financial products and services for its customers. Its focus on speed and convenience has made it a popular app for young people to own, not unlike Robinhood. Its member count has soared from 3.5 million in 2021 to more than 12.6 million people today. Its Rule of 40 score is 67%, as it has also been experiencing tremendous growth.

Today's Change

(

4.32

%) $

1.23

Current Price

$

29.72

It trades at a similar valuation to Robinhood, with its P/E ratio also around 50. Although it isn't a cheap stock to own, it can be a good one to hang on to for the long term, as it has proven to be a winner with retail investors.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued For Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company’s older devices.

Why did Inspire’s Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an “elongated timeframe” and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers “did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V,” that certain “software updates for claims submissions and processing did not take effect until July 1, [2025]” which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire’s customers had a backlog of older versions of the company’s device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

November 29, 2025 6:17 AM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2026.

SO WHAT: If you purchased Jayud securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Jayud was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Jayud's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about Jayud's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276054

Snapchat, an app whose disappearing messages and silly face filters made chatting with loved ones more casual, is close to a milestone that few social media platforms achieve: reaching 1 billion monthly users.

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) this week confirmed it will move forward with development of the Bilboes gold project following the release of a comprehensive feasibility study.

The company said the project contains approximately 2.3 million ounces of gold at a grade of over 2g/t, supporting a 10-year mine life with total production of 1.5 million ounces. Initial annual output is expected to reach 200,000 ounces.

Caledonia Mining said it plans to develop the project as a single-phase operation. The company noted this approach would generate stronger financial returns compared to a phased build. Peak capital expenditure is estimated at $484 million, with an additional $100 million allocated for financing-related items.

Using a gold price of $2,500 per ounce, the company reported a net present value of $580 million.

CEO Mark Learmonth joined the Proactive studio to talk us through the plans, and here, we take a closer look at what was said.

Proactive: Mark, good to have you along. Exciting news out from the company that you've made a decision to proceed on the Bilboes gold project. So, obviously, the results of the feasibility study have a lot to do with this. Take us through some of the key highlights that people should understand about the reasoning behind the decision.

Mark Learmonth: Yeah. We published an RNS this morning, and we've also published the full feasibility study — I think it is about 800 pages. Hopefully, the RNS gives a bit of an abbreviation, but it confirms that the project is a large high-grade project with just about 2.3 million ounces at over two grams a tonne, which is excellent for an open-pittable operation.

There's no change to the total production, which remains about 1.5 million ounces over ten years, although we've adjusted the phasing to bring more production forward, improving overall cash flow. In the first full year of production, we’re expecting about 200,000 ounces, which helps enormously.

CapEx has gone up — peak CapEx is now $484 million, plus another $100 million for things like interest. The increase isn't from scope changes but reflects inflation in input prices. However, that’s more than offset by the improved gold price.

Using a gold price of approximately $2,500, the NPV at 8% is just over $580 million. The ungeared IRR is over 32%. The all-in sustaining cost is $1,068 an ounce. So it's clearly a high-margin operation with a very quick payback — 1.7 years. At a higher gold price of $3,600, the NPV increases to $1.2 billion, and the IRR is 70% with a payback of just over a year.

Proactive: I want to pick up on something you talked about — the single-phased development approach you mentioned. Is it purely the economics that drove that decision?

Mark Learmonth: It is. We looked very closely at phased approaches to chop the CapEx into more manageable chunks. But the capital intensity of a smaller project increases — more dollars per ounce. That erodes the returns. So after reviewing and testing options, we decided to go with the big bang, single-phase approach.

Proactive: A lot of people ask about funding. Tell me a bit about the structure and how this is going to work.

Mark Learmonth: Given it’s a high-margin mine with a short payback, we believe senior non-recourse debt will provide most of the funding. The project has high debt capacity, but realistically, lenders may limit themselves to around 65–70% of the project value, which is still significant.

In addition, we’ve got the Blanket Mine, which will make a substantial contribution. As stated in the press release, we’ve entered into a three-year hedging arrangement locking in a minimum gold price of $3,500, which guarantees $200 million in cash flow from Blanket up to Caledonia.

That contributes substantially to the CapEx. And let me be clear: this is done with out-of-the-money put options — so no margin call risks, and we retain full upside participation if gold prices rise.

We’ll also consider hybrid instruments like streams or convertibles, but the goal is to minimise equity dilution. One of the reasons we've delivered strong returns over the past ten years is tight control over dilution. We aim to maintain that. I’m not saying there’ll be no equity dilution — but we’ll keep it tight.

Proactive: Okay. Timeline — what are you looking at?

Mark Learmonth: We’re starting the FEED phase — front-end engineering design — immediately. That takes about six months. Then we want to begin placing orders. There’s a big value uplift in starting this project sooner.

So we’re aiming to place orders for long-lead items in the second half of 2026. To do that, we’ll put short-term liquidity measures in place. Senior debt probably won’t flow until late 2026 or early 2027. Lenders move slowly, so we’re fast-tracking where we can.

We aim to begin construction in H2 2026, with initial production three years later — around late 2028. That’s an aggressive timetable and dependent on senior debt timing, but it’s our goal.

Proactive: Just a couple last questions from me. I imagine there's a lot of talk about this project in Zimbabwe. It's a boon for the economy, provides employment. A lot of eyes on it?

Mark Learmonth: You're right. It’ll be a marquee project in Zimbabwe. Gold production there has increased significantly due to high prices — this year’s output will be about 40 tonnes.

In its first year, Bilboes will add 6.5 tonnes — a significant contribution. It’ll also deliver substantial royalties, taxes, etc. We’re likely to make a fuller presentation early next year to wrap it all up.

But beyond the money, I think a project of this size helps Zimbabwe reclaim its position as a significant investment destination for gold. That’s long overdue.

Proactive: Last question — you mentioned a lot happening over the next three months to three years. What should people watch for?

Mark Learmonth: We’re close to year-end, so don’t expect much more in 2025. Key things to watch for in 2026 are progress on short-term liquidity measures, which will help us move faster.

Also, look for exploration updates — probably in February — at Blanket (both deep and shallow) and at Motapa, where we’re targeting sulphide material that would complement the Bilboes project. Expect that in early 2026.

Proactive: We'll keep an eye on all of that. Mark, thanks so much

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company’s fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its “inherent strength” and “the underlying momentum in our strategy.” The Company also stated on May 20, 2025, that it was seeing “normal stock levels” among its customers and that it was “seeing performance in the month to date as we would expect.”

As alleged, in truth, the Company’s North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered “in April through May” as customers “made efforts to return to more normal inventory levels[.]” The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

On November 17, 2025, James Hardie announced that Rachel Wilson had decided to step down from her role as CFO.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

Investors have until December 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.

Why Was MoonLake Sued for Securities Fraud?

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab (“SLK”), an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa (“HS”).

MoonLake told investors that its “strong clinical data,” including results from its Phase 2 MIRA trial, translate into “higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors.” The Company also stated that SLK’s Nanobody structure differed in beneficial ways from traditional monoclonal antibody treatments from its competitors.

As alleged, in truth, the Company’s clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug’s chances for regulatory approval and commercial viability.

The Stock Declines as the Truth Is Revealed

On September 28, 2025, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, with VELA-2 failing to meet its primary endpoint, calling into question the drug’s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 26, 2025, to $6.24 per share on September 29, 2025, the following trading day.

Click here for more information: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

What Can You Do?

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

Investors have until December 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410.

Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company’s Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company’s fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers “rely on Synopsys IP to minimize integration risk and speed time to market” and that it was seeing “strength in Europe and South Korea.” Synopsys also stated it was “continuing to develop and deploy[] AI into our products and the operations of our business.”

As alleged, in truth, the Company’s Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

The Stock Declines as the Truth Is Revealed

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its “IP business underperformed expectations.” The Company reported revenue for its Design IP segment of $425.9 million, a 7.7% decline year-over-year and net income of $242.5 million, a 43% year-over-year decline. The Company revealed that its Design IP customers require “more and more customization,” which “takes longer” and requires “more resources.” As a result, the Company stated it was having “an ongoing dialogue with our customers” regarding changing its business model. This news caused the price of Synopsys stock to fall $217.59 per share, or nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025.

Click here for more information: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

What Can You Do?

If you invested in Synopsys you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF) earlier this week confirmed that it had eliminated a key technical risk for its Phalaborwa project by adopting solvent extraction as its final separation method.

The company told investors that its previous approach - ion chromatography - had not achieved the required purity levels. By transitioning to solvent extraction, Rainbow was able to work with Australia’s Nuclear Science and Technology Organisation (ANSTO), which validated the ability to reach 99.5% purity for both Neodymium-Praseodymium and the SEG+ group.

Rainbow highlighted that its extraction circuits will be far smaller than traditional systems. It said the compact design, using just 75 mixer-settlers, supports low capital and operating costs.

CEO George Bennett joined the Proactive studio to talk about the project, this new milestone and rare earth market dynamics, and here, we take a closer look at what was said.

Proactive: George, good to speak with you. How does finalizing solvent extraction as the separation route materially de-risk Phalaborwa for investors?

George Bennett: Well, Rainbow always had this sort of risk discount to it because we were going down the path of ion chromatography for our final separation route, which has never been done commercially in rare earths before. But we looked at this as an alternative because we were very au fait with solvent extraction as a team, and also with continuous ion exchange.

So we thought ion chromatography could be a low capital-intensive method. We went down that path for a couple of years, but weren’t getting the purity and separation levels required. A year ago, we moved our pilot plant from Florida to South Africa and built our own lab, which significantly reduced costs and improved turnaround times on test results.

That allowed us to develop our flow sheet much quicker and at lower cost. We achieved a very high-grade leach solution and low impurity levels. That success allowed us to consider a smaller solvent extraction circuit.

Proactive: So how did ANSTO come into the picture?

George Bennett: We engaged ANSTO—Australia’s Nuclear Science and Technology Organisation—which is a global leader in solvent extraction for rare earths. They confirmed we could achieve 99.5% purity for both Neodymium-Praseodymium and the SEG+ group via two small solvent extraction circuits—just 75 mixer-settlers compared to up to 2,000 in some global projects.

This keeps us at the low end of capital and operating costs. It’s a significant de-risking step because we’re now using proven technology.

Proactive: George, yttrium prices have surged recently. How does this impact Phalaborwa’s EBITDA and what’s your view on sustainability of those prices?

George Bennett: Actually, we've seen even higher pricing in Europe—$220 to $320 per kilogram. That’s a 1,500% to 4,000% increase. Initially, we only expected value from Neodymium and Praseodymium, but now the SEG+ group adds significant value from dysprosium, terbium, yttrium, rhenium, and samarium.

Revenue from SEG+ could now reach around $160 million at 70% payability, versus $80 million previously. At EBITDA margins of 70–75%, that’s a major upside.

On sustainability, yttrium is critical for defense and aerospace. Since our announcement, a major aerospace and jet engine manufacturer has approached us for yttrium offtake at full pricing. With Chinese export restrictions likely due to military relevance, yttrium will remain a high-value rare earth.

Proactive: With ANSTO and METC Engineering onboard, what are the remaining technical milestones before the DFS is completed?

George Bennett: The key milestone—achieving separation and impurity thresholds—has now been met through solvent extraction. We’ll run a short pilot plant at ANSTO next year—seven days per circuit—to produce marketing samples.

From a technical standpoint, there's now nothing blocking the completion of the DFS, which we now expect in mid-2026. Previously, we couldn’t set a DFS timeline due to uncertainty in ion chromatography. That uncertainty is now removed.

Proactive: George, I hope you continue to keep us updated with your progress. Thank you for speaking with us.

There's a bit of confusion about how some basic market details have looked this year.

Bear markets are usually defined as periods when a market is down by at least 20% from a recent high. With that benchmark in mind, over the last couple of months, a popular story has emerged, claiming that the crypto sector's bull market ended back in January, and that the majority of 2025 has been one long bear market for the entire sector.

The story feels true because crypto portfolios are hurting right now. Lead assets like Bitcoin (BTC 1.20%), Ethereum (ETH 1.98%), Solana (SOL 3.64%), XRP (XRP 1.75%), Cardano, and even Dogecoin have spent the year grinding lower while the stock market roared higher, led by the "Magnificent Seven" group of stocks. So, is 2025 a bear market for crypto or not, and what should you actually do about it if it is?

Image source: Getty Images.

What 2025's drawdown actually looks like
Let's begin by looking at crypto as a whole rather than any single coin.

The global crypto market cap was around $3.8 trillion in mid-January before sliding sharply into the spring. It then recovered to reach a high of $4.3 trillion in early October, only to be devastated by the flash crash early in the month, and now rests at about $3.2 trillion.

Today's $3.2 trillion level represents something like a 16% slide from the start of the year, and roughly a 23% drop from the October peak. In stock market terms, that does indeed put the whole crypto sector somewhere between a sharp correction and the start of a bear market.

But at the individual coin level, it feels far worse than what that implies.

Take a look at this chart:

SPY data by YCharts

As you can see, Bitcoin's performance has been disappointing to most people. Ethereum is in the doldrums again after briefly showing signs of momentum. And Solana slumped despite a significant inflow of tokenized real-world assets (RWAs) to its chain.

In contrast, the stock market is up about 16% in 2025, even after the tariff-driven sell-off earlier in the year, and even amid substantial uncertainty in the economy. When you hold coins that are down double digits while the stock index funds are green, it certainly feels like a crypto bear market.

Today's Change

(

-1.20

%) $

-1101.28

Current Price

$

90582.00

The label matters less than your playbook
From here, there are two scenarios to consider.

First, this year's drawdown so far is simply a reset within a larger uptrend. In this world, the sharp October slide and the recent $1 trillion wipeout in crypto market value are painful but ultimately temporary, and not the start of a multiyear decline. If that's correct, continuing to accumulate high-quality coins is likely to yield favorable results over a long time horizon.

In the second scenario, the real bear market is still ahead. Crypto has just experienced a period of new exchange-traded funds (ETFs) and supportive policy moves for the first time. Without such catalysts to look forward to, investors could withdraw their capital and redirect it to greener pastures elsewhere. If this scenario proves to be true, the market will be well on its way to the depths of market conditions that crypto natives humorously refer to as "goblin town," and Bitcoin could fall by as much as another 50%, with altcoins expected to decline by 80% or more.

Today's Change

(

-1.98

%) $

-60.52

Current Price

$

2999.76

If the ongoing downturn attenuates into mere doldrums over the next month or so, it suggests that the first scenario is true. The best approach is to continue to dollar-cost average into Bitcoin, Ethereum, Solana, and XRP, as their recovery is likely to be around the corner. It might also be advisable to pick up some other altcoins on deep discounts, if your risk tolerance is high enough for it.

But if the sell-off accelerates or proves to be durable, the second scenario is more likely. Here, taking on risk too quickly with crypto majors or dabbling in altcoin investments is practically guaranteed to be deadly for your portfolio. The right approach is to become far more selective and cautious with your buying activity, and to concentrate your purchasing in proven assets like Bitcoin, which will definitely survive the bear market no matter how rough it gets.

Either way, understand that low prices will not be around for all cryptoassets forever, and if you're going to be in the market for at least the next five years or so, it's a better idea to be buying than to be sidelined, even if it feels scary to see prices falling. Bear markets often seem like they're the worst time to be looking for opportunity, but the truth is that opportunity is always there if you're willing to plan ahead.

XRP is witnessing a sharp return of bullish momentum after weeks of volatility, with buyers stepping back into the market at one of its most significant price levels. The token has rebounded decisively from $1.85, a support zone that has historically acted as a turning point during market corrections.

36 minutes ago

Bitcoin may be forming a local bottom as RSI nears oversold and whales open longs, fueling a possible relief rally toward the $100,000–$110,000 zone.

Bitcoin may be carving out a short-term bottom after weeks of heavy selling, with one market analyst arguing that conditions are in place for a relief rally toward the $100,000–$110,000 range.

In a recent video, trader Mister Crypto said Bitcoin (BTC)’s short-term structure shows signs of stabilization following what he described as “capitulation” across the market. He claimed that indicators tied to trader behavior suggest that large players have begun opening new long positions despite the sentiment plunging into extreme fear territory, a mix that has historically preceded bounces during downturns.

One of the main technical signals cited is the Bitcoin Relative Strength Index (RSI) on the weekly chart, which is approaching the 30 level. “We have bottomed out for Bitcoin right here. We have been reaching the 30 level. Boom,” he said.

The analyst noted that, in past cycles, this zone has coincided closely with market bottoms. While he cautioned that this does not guarantee the start of a new bull run, he said the current setup often signals at least a temporary reversal.

Bitcoin price performance after Thanksgiving. Source: Mister Crypto$102,000 level in focusAnother factor adding weight to the rebound scenario is Bitcoin’s distance from the 50-week moving average, currently near $102,000. According to the analysis, Bitcoin has repeatedly retraced toward this level after dipping below it in previous market cycles. The expectation now is a bounce that could lift prices back into six figures before any deeper trend emerges.

Macro conditions are also feeding optimism in the near term. The analyst pointed to expectations that quantitative tightening could soon end, combined with speculation around another interest rate cut at an upcoming policy meeting. Both developments tend to favor risk assets such as Bitcoin by easing financial conditions.

However, the longer-term outlook remains cautious. The analyst claimed that the broader market is in bear territory. He warned that any bounce could be followed by renewed weakness later on, as broader conditions have yet to show a decisive shift back into sustained growth.

Crypto sentiment lifts from ‘extreme fear’ After spending 18 days in “Extreme Fear,” the Crypto Fear & Greed Index finally lifted to a “Fear” level of 28.

Meanwhile, Bitwise Europe research head André Dragosch has said that Bitcoin could have major upside ahead, as its current price doesn’t reflect improving macro expectations. He said Bitcoin now offers an “asymmetric” risk-reward similar to the COVID crash of March 2020, when prices plunged before rebounding strongly, arguing the market is already pricing in an extremely bleak global outlook.

Magazine: 2026 is the year of pragmatic privacy in crypto — Canton, Zcash and more

An artificial intelligence model predicts that Ethereum (ETH) is likely to hold above the $3,000 support level by December 1. 

This outlook comes as ETH recovers alongside the broader market, reclaiming the $3,000 mark after days of extended losses that had raised the possibility of sustained declines below $2,000.

ETH price prediction 
For the December 1 price prediction, Finbold consulted OpenAI’s ChatGPT, which anticipates that Ethereum will trade near $3,360, with a realistic range of $3,300 to $3,420.

According to ChatGPT, recent market behavior shows Ethereum consistently attracting buyers in the $3,300 to $3,350 zone, forming a firm support base that limits downside risk. 

Exchange reserves have dropped to multi-year lows, suggesting immediate selling pressure is constrained as fewer coins are readily available on trading platforms.

Mildly bullish catalysts are also supporting an upward bias according to ChatGPT. Staking continues to reduce circulating supply, while DeFi and Layer-2 networks remain active. Markets are also positioning ahead of the December Fusaka upgrade, creating a subtle pre-event lift, though momentum is insufficient for a rapid breakout.

At the same time, market sentiment has stabilized following recent volatility, with no signs of panic, forced liquidations, or disorderly sell-offs. Open interest is firming, suggesting traders are cautiously re-entering positions, pointing toward a moderate rebound rather than a renewed decline.

Based on these fundamentals, ChatGPT noted that Ethereum’s ceiling remains well-defined, with repeated failures to break above the $3,880 to $4,000 resistance zone. This barrier is preventing a larger trend shift and limits how far the price can climb in the near term.

Weighing the current spot level near $3,000, the strong underlying support, and the cautiously improving sentiment backdrop, ChatGPT’s estimate places Ethereum’s most probable landing zone on December 1 at approximately $3,360.

Ethereum price probability distribution for Dec 1. Source: ChatGPT
ETH price analysis 
By press time, ETH was trading at $3,004, down 1.6% in the past 24 hours, while on the weekly timeline, the second-ranked cryptocurrency by market capitalization has gained over 10%.

ETH one-week price chart. Source: Finbold
Ethereum’s current level points to short-term bearish pressures relative to its simple moving averages (SMAs). The 50-day SMA sits at $3,509.66, with the current price 14% below it, highlighting recent downward momentum and potential resistance overhead if buyers attempt to reclaim this level.

Conversely, the 200-day SMA at $3,400.05 provides stronger long-term support, as ETH remains 12% above it, preserving a bullish structural bias and suggesting resilience against deeper corrections.

Complementing this, the 14-day Relative Strength Index (RSI) of 42.8 indicates neutral territory, far from overbought levels above 70 or oversold levels below 30, implying balanced conditions suitable for consolidation or a moderate upside.

Featured image via Shutterstock

Journalist

Posted: November 29, 2025

A big event came and went, and the crypto market barely reacted.

On the 28th of November, about 150,000 Bitcoin [BTC] options ($13.4 billion) and 573,000 Ethereum [ETH] options ($1.7 billion) expired, bringing the total to $15.4 billion. In short, this marked a major month-end expiry.

The interesting part? Positions were highly concentrated: BTC’s Put/Call Ratio hit 0.58, meaning more longs than shorts, with max pain around $100k. ETH was perfectly balanced at a 1.0 put/call ratio, max pain $3.4k.

Source: Deribit

And yet, despite the size of the expiry, the market barely moved. 

From a technical perspective, Bitcoin closed at $90,955, with a high of $93k, staying below its max pain level. For context, max pain is the price where option sellers (shorts) would sell BTC to limit their losses. 

In this case, since BTC stayed below $100k, sellers didn’t need to push the price around, and the market remained relatively calm. Hence, the real question is: Did this steadiness show Bitcoin’s underlying strength?

Clean flush and calm expiry point to Bitcoin bottom
The market is still trying to decide whether Bitcoin has truly bottomed.

In this context, BitMEX founder Arthur Hayes argued that BTC may have found a floor at $80k during the latest sell-off. He based this view on the possibility that the Fed is close to ending its Quantitative Tightening cycle.

At the same time, CryptoQuant noted that the market just saw the biggest Open Interest wipeout of this cycle. A sharp reset from about $45 billion down to $28 billion, which flushed out a lot of overheated positions.

Source: TradingView (BTC/USDT)

Put simply, the market just went through a clean flush.

With that backdrop, the $15 billion Bitcoin and Ethereum options expiry arrived at a time when leverage was already drained. In turn, this helps explain why the event came and went with barely any volatility.

At the same time, BTC holding around $90k in a risk-off environment, even with max pain way up at $100k showed that sellers didn’t need to push prices lower, and buyers were still stepping in to defend support.

In this context, this resilience could be an early sign of a Bitcoin bottom.

Final Thoughts

Despite massive BTC and ETH expiries, the market barely moved, showing low volatility as leverage had already been cleared.
Bitcoin remained around $90k, below max pain ($100k), suggesting buyers defended support and the market may be forming a floor.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network.
She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations.
At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.

Bitcoin is showing early signs of a powerful recovery after reclaiming the $90,000 region, following a dramatic correction on 20 November that pushed the market into panic. The Fear and Greed Index plunged to 12 during the decline, marking one of the most extreme fear readings since April.

Arthur Hayes criticizes Monad's MON token as a high-FDV, low-float model favoring early investors and exposing retail to volatility.

Sat, 29/11/2025 - 9:37

Binance's CZ has shared thoughts on what may be the best way to make the most out of Bitcoin, sparking debates across the crypto ecosystem.

Cover image via U.Today

Amid the consistent shift in the crypto market performance, which has seen Bitcoin steadily show mixed price action, Binance’s founder Changpeng Zhao has shared his thoughts on the best way to make the most out of the unstable market condition.

On Saturday, Nov. 29, CZ sparked a debate across the crypto community, airing what he considers as an unpopular opinion on the perfect time to buy and sell Bitcoin.

In his post, CZ suggested that the best way to maximize returns and easily navigate Bitcoin’s unpredictable cycles  is simply to sell when there is maximum greed, and buy when there is maximum fear.

HOT Stories

CZ's uncommon logic resonates with crypto communityWhile the statement has triggered fresh debates across the crypto community, it appears to have resonated with most crypto traders who believe that financial decisions should be made logically and not with emotions.

While CZ’s statement has come at a time when Bitcoin’s sentiment indicators are moving wildly between extremes as the recent Fear & Greed Index chart shows that market greed has soared to high levels during recent price rallies, fear spiked quickly during sharp pullback.

As such, commentators have expressed agreement to this narrative, emphasizing that traders should be watching closely rather than reacting emotionally to market conditions.

You Might Also Like

Although the logic is commonly echoed by seasoned investors, hearing it so bluntly from one of crypto’s most influential figures makes it a crucial reminder that market panic could be the perfect buying opportunity for traders.

Commentators further simplified the principle, noting that the best moves are often made when others are doing the opposite. While CZ had only used Bitcoin as an illustration, analysts further stated that the principle should be applied across all reliable cryptocurrencies to maximize returns.

Related articles

Greenidge Generation Holdings shut its New York mine after an electrical switchgear failure caused a fire, with operations expected to resume in weeks.

XRP had a good week, but what's next?

Ripple’s native token performed quite impressively in the past seven days, posting more notable price gains than many of its competitors. XRP is up by over 15% since this time last week, but it’s still down by double digits on a monthly scale.

What would happen to its price in the first week of the last month of 2025? We decided to ask OpenAI’s highly utilized AI solution.

XRP in the Week Ahead
ChatGPT argued that the most significant reason behind XRP’s weekly surge to $2.20 as of press time has been the recent launches of spot ETFs tracking its performance. Recall that Canary Capital’s XRPC was the first to hit the US markets in mid-November, followed by similar financial vehicles from Bitwise, Franklin Templeton, and Grayscale. In total, the products attracted over $660 million in net inflows in their first few weeks.

Nevertheless, the AI chatbot admitted that XRP remains in a “fragile position” as the market is yet to recover from the late October and Early November crash.

In terms of technical aspects, ChatGPT said the following for the week ahead:

RSI on the 4H and daily timeframes still shows “neutral recovery” rather than breakout conditions.

Volume increased on the upside move, but remains lower than during the selloff — a sign that buyers are cautious.

Bulls must reclaim $2.35–$2.40 to restart a larger trend reversal.

Continued inflows into the next XRP ETFs, aligned with improved sentiment on the Bitcoin market front, and some institutional adoption updates could propel Ripple’s cross-border token toward the aforementioned $2.40 resistance.

However, if the overall market conditions worsen again, or macro fears, such as rate cuts, intensify, then the asset might find itself dipping below $2.00 as it did earlier in November.

You may also like:

Binance XRP Reserves Sink to All-Time Low: Good or Bad for Ripple’s Price?

Ripple (XRP) Open Interest Crashes to 1-Year Low: Here’s What It Means

The Second XRP ETF Hits US Markets Today: Here’s How It’s Going So Far

Most Likely Scenario
The AI chatbot believes the most likely scenario for the week ahead is a consolidation phase, meaning XRP will remain sideways, with a lower boundary at $2.18 and an upper one at $2.35. The less viable options would be a bear case and a drop to the $2.00 support, or a more bullish move toward $2.55, but only if the ETF inflows skyrocket or whales change their recent behavior and start to accumulate hard.

“XRP has stabilized impressively after a turbulent month, but the market still shows signs of hesitation. The most realistic expectation is a consolidation between $2.18 and $2.35, with a potential breakout toward $2.50 if bullish catalysts line up,” concluded ChatGPT.

Tags:

TL;DR

Monad Overview: A high-performance, EVM-compatible layer-1 blockchain designed to scale DeFi, payments, and institutional finance.
MON Token Utility: Native cryptocurrency powering transactions, governance, and security, with wide distribution via sales and airdrops.
Price Predictions 2026–2032: Forecasts range from cautious lows near $0.0075 to ambitious highs above $0.55, reflecting adoption, liquidity, and ecosystem maturity.

Monad is a layer-1 blockchain designed to deliver high performance and scalability for decentralized applications. Built with EVM compatibility, it aims to extend Ethereum’s virtual machine into a faster, more efficient environment. By addressing common challenges such as high transaction fees and slow block confirmations, Monad positions itself as a next-generation solution for DeFi, payments, and institutional-grade finance.

The Native Token: MON
At the core of the ecosystem lies MON, the native cryptocurrency of the Monad blockchain. With a total supply of 100 billion tokens, MON was launched through a combination of public sales and airdrops, ensuring wide distribution among users. The token plays a crucial role in powering transactions, securing the network, and enabling participation in governance. Early trading activity has shown mixed reactions, but MON remains central to Monad’s long-term vision of scaling blockchain adoption.

From Fundamentals to Forecasts
As Monad continues to evolve, its technological promises and tokenomics will shape how MON performs in the coming years. With its foundation now established, the next step is to explore price predictions for MON between 2026 and 2032, analyzing potential growth trajectories and market dynamics.

2026: Early Momentum and Market Signals
According to CoinCocex, in 2026 MON is expected to trade within a channel between $0.007524 and $0.03029, settling at an average annualized price of $0.01385. This projection implies a potential return on investment of -16.92%, signaling caution for long-term holders.

From other market analyses, attention in 2026 is likely to center on ecosystem growth and liquidity depth. If adoption expands and network usage accelerates, MON could potentially sustain a stronger trading range between $0.10 and $0.18 throughout the year.

Youtubers Price Prediction for Monad
Cilinix Crypto, a well-known YouTube channel, has shared a video analyzing MON price predictions, delivering timely insights into market trends, technical indicators, and investor sentiment shaping the cryptocurrency’s outlook.

2027: Consolidation Phase and Investor Confidence

CoinDataFlow’s experimental price simulation model indicates that MON could see a modest increase of 13.64% in 2027, with its value potentially reaching $0.040711 in the best-case scenario. Throughout the year, the token is expected to fluctuate within a range between $0.040711 and $0.015497, reflecting both upside potential and downside risks.

Meanwhile, other market perspectives emphasize the importance of long-term adoption and ecosystem maturity by 2027. If MON achieves meaningful traction in DeFi and payments, while sustaining developer engagement, its price could consolidate within a stronger band between $0.14 and $0.25.

2028: Scaling Adoption Across DeFi and Beyond
DigitalCoinPrice suggests that 2028 could mark a pivotal year for MON, with the possibility of its value doubling compared to prior levels. The forecast anticipates an all-time high between $0.15 and $0.16, though it also acknowledges that the token may fall short of reaching the upper bound.

From broader market perspectives, 2028 is expected to favor chains with strong developer communities and stable liquidity, which often consolidate into predictable trading zones. If MON achieves this stage of maturity, its price could stabilize within a higher range between $0.20 and $0.32.

2029: Navigating Volatility in Global Markets

Projections for 2029 suggest that the trajectory of MON adoption will continue its upward trend under increasing regulatory oversight. Investors may observe a peak price point of $0.20702, followed by a trough of $0.185604, with the mean price for the year expected to converge around $0.196312.

Looking ahead, analysts highlight that MON’s valuation in 2029 will depend heavily on network share, utility, and supply absorption. If ecosystem incentives remain strong and activity expands, the token could move into a higher trading region between $0.28 and $0.40.

2030: Long-Term Growth and Institutional Entry
By 2030, MON is anticipated to trade within a channel ranging from $0.01896 to $0.04720, with the average annualized price converging around $0.02911. This projection suggests a potential return on investment of 17.82%, reflecting moderate growth compared to earlier years. The outlook highlights a cautiously optimistic scenario.

Analysts also point to a more ambitious scenario in which consistent network activity and competitive performance could push MON toward the upper end of its long-term range. In this case, a mature ecosystem supported by strong developer presence and sustained utility may lift the token toward $0.55.

2031: Strategic Partnerships Driving Value Creation

Expert findings and experimental price prediction simulations suggest that Monad could experience a significant rise of 283.16% in 2031, potentially reaching $0.137261 under the most positive scenario. Throughout the year, the token is expected to remain within a trading range between $0.137261 and $0.05608, reflecting both the potential for substantial growth and the risks of volatility.

Technical analysis and alternative forecasts present a more ambitious outlook for 2031. Predictions indicate that the cost of Monad could reach $0.26 at the beginning of the year and maintain that level by year’s end, with additional scenarios suggesting prices up to $0.24 during the same period.

2032: Future Outlook and Sustainability of MON
Forecasts for 2032 suggest that Monad could begin the next decade with a potential peak price of $0.314099, while the minimum price point may hover around $0.292683. Technical indicators and market trends project an average annualized price of approximately $0.303391, signaling steady growth compared to prior years.

Analysts further anticipate that by 2032, MON could surpass the $0.36 average price level. Toward the end of the year, forecasts point to a minimum price of $0.35, with the possibility of reaching a maximum of $0.37. This more optimistic projection underscores the potential for MON to consolidate at higher valuations.

Conclusion
Monad (MON) emerges as a promising layer-1 blockchain focused on scalability, efficiency, and EVM compatibility, positioning itself as a next-generation solution for DeFi and institutional finance. Its native token plays a central role in transactions, governance, and network security, with wide distribution ensuring community participation. Price forecasts from 2026 to 2032 highlight both cautious scenarios and ambitious growth trajectories, ranging from early volatility to potential highs above $0.55.

The Price Predictions published in this article are based on estimates made by industry professionals; they are not investment recommendations, and it should be understood that these predictions may not occur as described.

The content of this article should only be taken as a guide, and you should always carry out your own analysis before making any investment.

Chainlink price dropped for three consecutive days and remains in a deep bear market despite important catalysts like the upcoming LINK ETF approval and falling exchange reserves.

Summary

Chainlink price remained under pressure this month.
The supply of LINK tokens in exchanges has dived.
Grayscale will launch the spot LINK ETF next week.

Chainlink (LINK) token dropped to $13, down by ~53% from its highest level in September, a move that has erased billions of dollars in value. 

LINK price has crashed despite notable bullish catalysts. One of them is that Grayscale will launch its LINK ETF next week. As one of the top utility tokens in the crypto industry, this ETF will likely lead to substantial demand from investors. 

Some top utility tokens have had robust demand. For example, spot Solana (SOL) ETFs have had over $618 million in inflows and are now nearing the $1 billion mark in terms of assets. 

Similarly, spot XRP ETFs have added over $666 million in inflows, a sign that the demand is accelerating. All XRP ETFs now have $687 million in assets, a trend that may accelerate in the near term. 

The other notable catalyst for Chainlink price is that its supply in exchanges has continued falling. Nansen data shows that this supply has been in a freefall and now stands at 214 million, down sharply from 275 million. 

Chainlink exchange balances are falling | Source: Nansen
Falling LINK reserves is a sign that demand is rising, with more investors moving their tokens to exchanges. One minor reason why this is happening is that Chainlink has continued to add more tokens to its strategic reserves. These reserves are nearing 1 million, a few months after they were launched.

Chainlink price technical analysis
LINK price chart | Source: crypto.news
The weekly chart shows that Chainlink price has formed an alarming pattern and is now sitting at an important support. It has formed a head-and-shoulders pattern, a common bearish reversal sign.

LINK price has moved to the neckline of this pattern. It has moved below the 100-week Exponential Moving Average and the Supertrend indicator. 

Therefore, the most likely Chainlink forecast is bearish, with the next target to watch being at $10, down by 22% from the current level. A move below that level will point to more downside, potentially to the 2023 low of $8.